journal
https://read.qxmd.com/read/38531863/how-comparable-are-patient-outcomes-in-the-real-world-with-populations-studied-in-pivotal-aml-trials
#1
JOURNAL ARTICLE
Ing Soo Tiong, Meaghan Wall, Ashish Bajel, Akash Kalro, Shaun Fleming, Andrew W Roberts, Nisha Thiagarajah, Chong Chyn Chua, Maya Latimer, David Yeung, Paula Marlton, Amanda Johnston, Anoop Enjeti, Chun Yew Fong, Gavin Cull, Stephen Larsen, Glen Kennedy, Anthony Schwarer, David Kipp, Sundra Ramanathan, Emma Verner, Campbell Tiley, Edward Morris, Uwe Hahn, John Moore, John Taper, Duncan Purtill, Pauline Warburton, William Stevenson, Nicholas Murphy, Peter Tan, Ashanka Beligaswatte, Howard Mutsando, Mark Hertzberg, Jake Shortt, Ferenc Szabo, Karin Dunne, Andrew H Wei
Despite an increasing desire to use historical cohorts as "synthetic" controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow cytometry, and molecular features linked to treatment received (including transplantation), response to treatment, relapse, and survival outcome...
March 26, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38531841/outcomes-of-patients-with-multiple-myeloma-refractory-to-standard-dose-vs-low-dose-lenalidomide
#2
JOURNAL ARTICLE
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalves, Suzanne R Hayman, Miriam A Hobbs, Yi L Hwa, Taxiarchis Kourelis, Martha Q Lacy, Nelson Leung, Yi Lin, Rahma M Warsame, Robert A Kyle, S Vincent Rajkumar, Shaji K Kumar
Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance to lenalidomide varies among MM refractory to standard doses vs low dose maintenance doses. In this study, we assessed the outcomes with subsequent therapies in patients with MM refractory to standard dose vs low dose lenalidomide. We retrospectively reviewed all patients with MM at our institution who received first line therapy with lenalidomide containing regimens, and assessed progression free survival (PFS) and overall survival for these patients for second line therapy, and with lenalidomide retreatment...
March 26, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38531834/a-successful-treatment-free-remission-is-achievable-also-by-chronic-myeloid-leukemia-patients-lacking-optimal-requirements
#3
LETTER
Massimiliano Bonifacio, Luigi Scaffidi, Maria Cristina Miggiano, Davide Facchinelli, Luca Tosoni, Sara Pezone, Davide Griguolo, Giulia Ciotti, Marco Danini, Andrea Bernardelli, Rita Bresciani, Monica Cavraro, Lara Crosera, Elena De March, Michele Dell'Eva, Laura Dorotea, Luca Frison, Lara Furlani, Ilaria Gianesello, Ester Lovato, Elena Marchetti, Gianluca Morelli, Rikard Mullai, Umberto Pizzano, Simone Zoletto, Renato Fanin, Mauro Krampera, Livio Trentin, Elisabetta Calistri, Giuseppe Carli, Gianni Binotto, Mario Tiribelli
No abstract text is available yet for this article.
March 26, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38519476/once-weekly-versus-twice-weekly-bortezomib-in-newly-diagnosed-multiple-myeloma-a-real-world-analysis
#4
JOURNAL ARTICLE
Fieke W Hoff, Rahul Banerjee, Adeel M Khan, Georgia McCaughan, Bo Wang, Xiaoliang Wang, James Roose, Larry D Anderson, Andrew J Cowan, S Vincent Rajkumar, Gurbakhash Kaur
Induction regimens for multiple myeloma (MM) commonly include bortezomib, which has typically been administered twice weekly despite studies demonstrating comparable efficacy and less peripheral neuropathy (PN) with once-weekly bortezomib. We aimed to analyze the real-world prevalence and efficacy of once-weekly versus twice-weekly bortezomib regimens in newly diagnosed MM. We analyzed 2497 US patients aged 18-70 years treated with commercial first-line bortezomib using nationwide Flatiron Health electronic health record-derived data, including 910 (36...
March 22, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38503764/calr-type-1-like-mutation-in-myelofibrosis-is-the-most-prominent-predictor-of-momelotinib-drug-survival-and-longevity-without-transplant
#5
LETTER
Ayalew Tefferi, Animesh Pardanani, Kebede H Begna, Aref Al-Kali, William J Hogan, Mark R Litzow, Rhett P Ketterling, Kaaren K Reichard, Naseema Gangat
No abstract text is available yet for this article.
March 19, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38499538/progression-free-survival-of-myeloma-patients-who-become-ife-negative-correlates-with-the-detection-of-residual-monoclonal-free-light-chain-flc-by-mass-spectrometry
#6
JOURNAL ARTICLE
H V Giles, M T Drayson, B Kishore, C Pawlyn, M Kaiser, G Cook, R de Tute, R G Owen, D Cairns, T Menzies, F E Davies, G J Morgan, G Pratt, G H Jackson
Deeper responses are associated with improved survival in patients being treated for myeloma. However, the sensitivity of the current blood-based assays is limited. Historical studies suggested that normalisation of the serum free light chain (FLC) ratio in patients who were negative by immunofixation electrophoresis (IFE) was associated with improved outcomes. However, recently this has been called into question. Mass spectrometry (MS)-based FLC assessments may offer a superior methodology for the detection of monoclonal FLC due to greater sensitivity...
March 18, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38499533/genetically-determined-telomere-length-and-risk-for-haematologic-diseases-results-from-large-prospective-cohorts-and-mendelian-randomization-analysis
#7
LETTER
Yang Li, Jia Chen, Ting Sun, Yunfei Chen, Rongfeng Fu, Xiaofan Liu, Feng Xue, Wei Liu, Mankai Ju, Xinyue Dai, Huan Dong, Huiyuan Li, Wentian Wang, Ying Chi, Lei Zhang
No abstract text is available yet for this article.
March 18, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38499527/treatment-emergent-mutations-in-myelodysplastic-syndrome-with-del-5q-lenalidomide-related-or-disease-intrinsic-clonal-evolution
#8
LETTER
Mostafa Abdallah, Kaaren Reichard, Naseema Gangat, Ayalew Tefferi
No abstract text is available yet for this article.
March 18, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38499521/momelotinib-for-myelofibrosis-our-14-years-of-experience-with-100-clinical-trial-patients-and-recent-fda-approval
#9
EDITORIAL
Ayalew Tefferi, Animesh Pardanani
No abstract text is available yet for this article.
March 18, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38485926/in-vivo-expression-of-anti-cd19-cd3-bite-by-liver-targeted-aav-for-the-treatment-of-b-cell-malignancies
#10
LETTER
Zhiqiang Song, Ping Liu, Dongliang Zhang, Tao Wang, Wenqin Yue, Yuke Geng, Na Liu, Yang Wang, Jianmin Yang
No abstract text is available yet for this article.
March 15, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38485723/ptcy-versus-atg-as-graft-versus-host-disease-prophylaxis-in-mismatched-unrelated-stem-cell-transplantation
#11
JOURNAL ARTICLE
Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Zafer Gülbas, Tobias Gedde-Dahl, Cristina Castilla-Llorente, Nicolaus Kröger, Mathias Eder, Alessandro Rambaldi, Francesca Bonifazi, Igor Wolfgang Blau, Matthias Stelljes, Peter Dreger, Ivan Moiseev, Hélène Schoemans, Christian Koenecke, Zinaida Peric
There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it is standard practice to use rabbit anti-thymocyte globulin (rATG) to reduce the high NRM and GVHD risks after MMUD alloSCT. As an alternative to rATG, post-transplantation Cyclophosphamide (PTCy) is in increasing clinical use. It is currently impossible to give general recommendations regarding preference for one method over another since comparative evidence from larger data sets is lacking...
March 15, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38480693/age-specific-survival-in-acute-myeloid-leukemia-in-the-nordic-countries-through-a-half-century
#12
LETTER
Kari Hemminki, Frantisek Zitricky, Asta Försti, Mika Kontro, Bjorn T Gjertsen, Marianne Tang Severinsen, Gunnar Juliusson
No abstract text is available yet for this article.
March 14, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38467614/large-differencies-in-age-specific-survival-in-multiple-myeloma-in-the-nordic-countries
#13
LETTER
Kari Hemminki, Frantisek Zitricky, Asta Försti, Raija Silvennoinen, Annette Vangsted, Markus Hansson
No abstract text is available yet for this article.
March 11, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38453907/regulation-of-hox-gene-expression-in-aml
#14
REVIEW
Irum Khan, Mohammed A Amin, Elizabeth A Eklund, Andrei L Gartel
As key developmental regulators, HOX cluster genes have varied and context-specific roles in normal and malignant hematopoiesis. A complex interaction of transcription factors, epigenetic regulators, long non-coding RNAs and chromatin structural changes orchestrate HOX expression in leukemia cells. In this review we summarize molecular mechanisms underlying HOX regulation in clinical subsets of AML, with a focus on NPM1 mutated (NPM1mut ) AML comprising a third of all AML patients. While the leukemia initiating function of the NPM1 mutation is clearly dependent on HOX activity, the favorable treatment responses in these patients with upregulation of HOX cluster genes is a poorly understood paradoxical observation...
March 7, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38448432/reducing-and-controlling-metabolic-active-tumor-volume-prior-to-car-t-cell-infusion-can-improve-survival-outcomes-in-patients-with-large-b-cell-lymphoma
#15
JOURNAL ARTICLE
Kylie Keijzer, Janneke W de Boer, Jaap A van Doesum, Walter Noordzij, Gerwin A Huls, Lisanne V van Dijk, Tom van Meerten, Anne G H Niezink
Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients with relapsed or refractory Large B-cell lymphoma (r/r LBCL). This study aimed to assess the influence of quantified MATV and MATV-dynamics, between pre-apheresis (baseline) and pre-lymphodepleting chemotherapy (pre-LD) MATV, on CAR T-cell outcomes and toxicities in patients with r/r LBCL. MATVs were calculated semi-automatically at baseline (n = 74) and pre-LD (n = 68) in patients with r/r LBCL who received axicabtagene ciloleucel...
March 7, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38448422/correction-gprc5d-as-a-novel-target-for-the-treatment-of-multiple-myeloma-a-narrative-review
#16
Paula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar Bahlis, Ajai Chari
No abstract text is available yet for this article.
March 6, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38448401/clinical-outcomes-of-patients-with-lymphoid-blastic-phase-of-chronic-myeloid-leukemia-treated-with-car-t-cell-therapy
#17
LETTER
Yujie Liu, Yuqing Tu, Jinyan Xiao, Yifan Shen, Biqi Zhou, Qiannan Yang, Lei Yu, Lijuan Qi, Jia Chen, Tianhui Liu, Depei Wu, Yang Xu
No abstract text is available yet for this article.
March 6, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38443358/enhancing-prognostic-power-in-multiple-myeloma-using-a-plasma-cell-signature-derived-from-single-cell-rna-sequencing
#18
JOURNAL ARTICLE
Jian-Rong Li, Shahram Arsang-Jang, Yan Cheng, Fumou Sun, Anita D'Souza, Binod Dhakal, Parameswaran Hari, Quillan Huang, Paul Auer, Yong Li, Raul Urrutia, Fenghuang Zhan, John D Shaughnessy, Siegfried Janz, Jing Dong, Chao Cheng
Multiple myeloma (MM) is a heterogenous plasma cell malignancy, for which the established prognostic models exhibit limitations in capturing the full spectrum of outcome variability. Leveraging single-cell RNA-sequencing data, we developed a novel plasma cell gene signature. We evaluated and validated the associations of the resulting plasma cell malignancy (PBM) score with disease state, progression and clinical outcomes using data from five independent myeloma studies consisting of 2115 samples (1978 MM, 65 monoclonal gammopathy of undetermined significance, 35 smoldering MM, and 37 healthy controls)...
March 6, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38443356/unrelated-donor-hematopoietic-stem-cell-transplantation-compared-to-immunosuppressive-therapy-plus-eltrombopag-as-first-line-treatment-for-adults-with-severe-aplastic-anemia
#19
LETTER
Liangliang Wu, Limin Liu, Xin Zhao, Ming Zhou, Andie Fu, Yuping Zhang, Wenrui Yang, Xiaowei Chen, Wenjian Mo, Caixia Wang, Yumiao Li, Shilin Xu, Shiyi Pan, Ruiqing Zhou, Fankai Meng, Fengkui Zhang, Depei Wu, Shunqing Wang
No abstract text is available yet for this article.
March 6, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38443345/teclistamab-in-relapsed-refractory-multiple-myeloma-multi-institutional-real-world-study
#20
MULTICENTER STUDY
Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Samer Al-Hadidi, Dennis Cooper, Suzanne Lentzsch, Frits van Rhee, Anita D'Souza, Aniko Szabo, Carolina Schinke, Rajshekhar Chakraborty
The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of teclistamab up until August 2023. One hundred and ten patients were included, of whom, 86% had triple-class refractory disease, 76% penta-refractory disease, and 35% had prior exposure to B-cell maturation antigen (BCMA)-targeting therapies...
March 5, 2024: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.